Leuprolide mesylate

甲磺酸亮丙瑞林

Report date: 2026/03/30 17:02:26

Base Information

Drug NameLeuprolide mesylate
Drug Alias Nameleuprolide controlled-release - Foresee/ScinoPharmaLeuprolide Mesylate - Foresee/ScinoPharmaleuprorelin mesilateCAMCEVICamcevi Kit +[8] 
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionGonadotropin-releasing hormone agonists
TargetsGonadotropin-releasing hormone
Therapy Area/IndicationsPuberty, PrecociousProstatic NeoplasmsBreast Neoplasms
Global Approved IndicationsProstatic Neoplasms
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2021/05/25
Country/TerritoryCzechiaUnited StatesSlovakia +[11] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesForesee Pharmaceuticals Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesForesee Pharmaceuticals Co LtdAccord Healthcare SluAccord Biopharma Inc +[6] 
Inactive CompaniesOhio State University Comprehensive Cancer Center
Active IndicationsPuberty, PrecociousProstatic NeoplasmsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeL02AE02
Related LinksN/A